You trained for six months. Your VO2max is elite. You land in Cusco at 3,400m — and by evening you can't sleep, your head is splitting, and your heart rate won't drop below 90 bpm at rest.
Fitness offers almost zero protection against acute mountain sickness (AMS). Here's why — and what the evidence actually says about prevention.
---
Acute mountain sickness is caused by hypobaric hypoxia: the partial pressure of oxygen (pO₂) drops linearly with altitude. At 3,000m, inspired pO₂ is roughly 30% lower than at sea level. Your cardiovascular system compensates with tachycardia and increased ventilation, but peripheral and cerebral vasodilation driven by hypoxia can cause fluid shifts and mild cerebral oedema — the root mechanism behind AMS symptoms.
The diagnosis uses the Lake Louise Score (LLS): headache plus at least one of fatigue, gastrointestinal distress, dizziness, or difficulty sleeping. A score ≥3 within 6–12 hours of ascent indicates AMS. Critically, Roach et al. (1993) showed incidence ranges from 10–25% at 2,500m up to 40–60% at 4,500m — regardless of aerobic fitness level.
---
The ascent rate is the single most modifiable risk factor. Current Wilderness Medical Society guidelines recommend ascending no faster than 300–500m per day above 2,500m, with a rest day every 1,000m of altitude gained. The underlying logic: erythropoiesis (new red blood cell production driven by hypoxia-inducible factor HIF-1α) takes 2–3 weeks to meaningfully elevate haemoglobin, but ventilatory acclimatisation begins within hours — if given time.
Sleeping altitude matters more than daytime altitude. The mountaineering maxim *climb high, sleep low* reflects real physiology: nocturnal hypoxia is when cerebral oedema risk peaks, coinciding with reduced respiratory drive during sleep and amplified periodic breathing (Cheyne-Stokes respiration).
---
Acetazolamide (Diamox) is the evidence-based pharmacological option. It inhibits carbonic anhydrase, forcing bicarbonate excretion and creating a mild metabolic acidosis that stimulates deeper breathing — effectively mimicking acclimatisation. Hackett and Roach (2001) confirmed 125–250mg twice daily reduces AMS incidence by ~50%. Side effects include tingling extremities and increased urination; it should not be used as a substitute for proper ascent rate.
For those preferring non-pharmacological prophylaxis, ibuprofen 400mg three times daily has demonstrated AMS prevention comparable to acetazolamide in a double-blind RCT (Verhagen et al., 2012, British Medical Journal). The mechanism involves COX inhibition reducing prostaglandin-mediated vasodilation and cerebral oedema.
Hydration is frequently overcorrected. Aggressive over-drinking at altitude can worsen hyponatraemia; the evidence supports drinking to thirst rather than forcing intake.
---
Knowing when to descend is non-negotiable. HACE (high altitude cerebral oedema) and HAPE (high altitude pulmonary oedema) are life-threatening progressions from AMS. HACE presents with ataxia and altered consciousness; HAPE with pink frothy sputum and extreme dyspnoea at rest. Both require immediate descent of at least 500–1,000m, supplemental oxygen if available, and — in remote settings — portable hyperbaric chambers (Gamow bag).
The tragedy of altitude emergencies is that most are preventable with simple arithmetic: plan your ascent profile, monitor symptoms with the Lake Louise Score daily, and never ascend with unresolved symptoms.
For outdoor athletes planning trekking, cycling at altitude, or expedition racing, the free risk assessment tool at winsport.uk/tools/health/outdoor-safety-risk-calculator models your environmental exposure — including altitude, WBGT heat load, and UV index — so you can prepare with real numbers, not guesswork.
Have you ever experienced AMS on a trip you thought you'd planned perfectly? What was the variable you underestimated?